Putnam BioRevolution ETF (SYNB)
- Previous Close
29.15 - Open
29.41 - Bid 26.60 x 1000
- Ask 32.26 x 1300
- Day's Range
29.43 - 29.49 - 52 Week Range
24.47 - 31.10 - Volume
602 - Avg. Volume
201 - Net Assets 5.43M
- NAV 29.45
- PE Ratio (TTM) 25.23
- Yield 0.07%
- YTD Daily Total Return 1.32%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.70%
The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on “biology revolution” companies. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors. The fund is non-diversified.
Franklin Templeton Investments
Fund Family
Health
Fund Category
5.43M
Net Assets
2022-09-29
Inception Date
Performance Overview: SYNB
Trailing returns as of 4/26/2024. Category is Health.
People Also Watch
Holdings: SYNB
Top 10 Holdings (53.51% of Total Assets)
Sector Weightings
Recent News: SYNB
Research Reports: SYNB
Analyst Report: Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingPrice TargetAnalyst Report: Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
RatingPrice TargetAnalyst Report: Baxter International Inc.
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off in 2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
RatingPrice TargetAnalyst Report: Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
RatingPrice Target